Key Highlights
- Dr. Shafique Virani appointed as Chief Business Officer at Noetik, a leader in AI-enabled precision cancer immunotherapies.
- Brings extensive experience from roles at Recursion, Navire Pharma, and Roche/Genentech, enhancing Noetik’s strategic partnerships and therapeutic pipeline.
- Aims to accelerate Noetik’s mission by identifying impactful transactions and transitioning the therapeutic pipeline to clinical trials.
Source: Business Wire
Notable Quotes
- “Shaf brings a unique combination of skills, bridging pharmaceutical business acumen with clinical development insight,” – Jacob Rinaldi, Ph.D., CSO & Co-Founder at Noetik
- “We are thrilled to welcome Shaf to our team as Chief Business Officer. His unique expertise… will be massively impactful in turning innovative scientific insights into differentiated therapeutics.” – Ron Alfa, M.D., Ph.D., CEO & Co-Founder at Noetik
- “Joining Noetik as Chief Business Officer was an obvious decision… Together, we’re set to redefine what’s possible in our industry, driven by a shared vision for transformative impact on patients.” – Dr. Shafique Virani, Chief Business Officer at Noetik
SoHC's Take
Dr. Shafique Virani’s appointment as Chief Business Officer at Noetik marks a significant milestone for the company in its pursuit of revolutionizing cancer treatment through AI-native technologies. His vast experience in fostering strategic partnerships and advancing therapeutic portfolios will be invaluable in Noetik’s journey towards developing precision cancer immunotherapies. This move underscores Noetik’s commitment to blending cutting-edge technology with top-tier talent to impact patient care profoundly. As the industry continues to evolve, the collaboration between AI and biotech will play a pivotal role in shaping the future of cancer therapy, with Noetik leading the charge.
